Press release
Osteogenesis Imperfecta Market to Expand Significantly by 2034 with Advancements in Novel Therapies and Rising Disease Awareness, Reports DelveInsight
Osteogenesis Imperfecta Market
The Osteogenesis Imperfecta (OI) market is expected to witness notable growth over the coming years, driven by increasing awareness, advancements in treatment approaches, and ongoing research in rare genetic disorders. According to DelveInsight, the Osteogenesis Imperfecta market size across the 7MM was approximately USD 30 million in 2023 and is projected to grow at a significant CAGR through 2034.
DelveInsight's latest report, "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast - 2034," provides a comprehensive evaluation of the disease landscape, including historical and forecasted epidemiology and evolving therapeutic trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover key Osteogenesis Imperfecta market trends, treatment advancements, and emerging therapies shaping the future landscape. Access the sample report here: https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market [https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Highlights from the Osteogenesis Imperfecta Market Report
* On December 15, 2025, Ultragenyx Pharmaceutical Inc. initiated a clinical study exclusively in Japan. The study includes a screening phase, followed by an open-label treatment period and an extension phase. Patients enrolled in the study will receive setrusumab therapy for up to 24 months during the treatment phase, followed by continued administration in the extension period. Treatment will continue until the therapy becomes commercially available in Japan, consent is withdrawn, or the study is terminated.
* On December 12, 2025, Amgen announced a Phase III clinical trial to evaluate romosozumab over a 12-month period compared to bisphosphonate therapies. The study aims to assess outcomes such as reduction in clinical fractures, overall fracture incidence, and improvement in lumbar spine bone mineral density (BMD) scores.
* In 2023, the total prevalent population of Osteogenesis Imperfecta in the United States was estimated at approximately 40,000 cases, and this number is expected to rise during the forecast period.
* Within the U.S., around 20,000 cases were associated with COL1A1 gene mutations, nearly 7,000 cases were linked to COL1A2 mutations, and approximately 800 cases were attributed to other genetic variants in 2023.
* Among the EU4 countries and the United Kingdom, Germany reported the highest share of OI prevalence at nearly 25%, followed by France at around 20% in 2023.
* Globally, Osteogenesis Imperfecta prevalence is estimated to range between 6 to 7 cases per 100,000 individuals, with severity varying depending on genetic mutations.
* In the 7MM, Japan contributed approximately 10% to the total treated OI cases in 2023, indicating a smaller yet important market segment.
* Leading companies operating in the Osteogenesis Imperfecta space include Amgen, UCB, Ultragenyx Pharmaceuticals, Angitia, Sanofi, Mereo BioPharma, among others.
* Prominent therapies under development or in use include UX143 (setrusumab), EVENITY (romosozumab), PROLIA (denosumab), and additional pipeline candidates.
Align your business strategies with evolving Osteogenesis Imperfecta market dynamics, request a sample report today: https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market [https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Osteogenesis Imperfecta: Disease Overview
Osteogenesis Imperfecta is a rare, inherited connective tissue disorder primarily characterized by brittle bones that fracture easily, often with minimal trauma. The condition arises due to defects in the production or structure of type I collagen, a critical component of bone strength.
The clinical presentation of OI varies widely, ranging from mild forms with infrequent fractures to severe, life-threatening cases involving multiple fractures, skeletal deformities, and growth impairments. Additional symptoms may include blue sclera, hearing loss, dental abnormalities (dentinogenesis imperfecta), joint laxity, and cardiopulmonary complications in severe cases.
Osteogenesis Imperfecta Epidemiological Segmentation in the 7MM
The report provides detailed epidemiological segmentation of Osteogenesis Imperfecta across the seven major markets, including:
* Total prevalent cases of Osteogenesis Imperfecta
* Diagnosed patient population
* Gene-specific mutation cases
* Type-specific distribution
* Total treated cases
Explore detailed Osteogenesis Imperfecta epidemiological insights and prevalence trends: https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market [https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Osteogenesis Imperfecta Treatment Landscape
The Osteogenesis Imperfecta treatment market is evolving steadily, supported by increasing recognition of the disease and improvements in diagnostic capabilities. Treatment strategies primarily focus on reducing fracture risk, enhancing bone strength, and improving overall quality of life.
Current management approaches involve a combination of pharmacological treatments, surgical interventions, and supportive therapies. Bisphosphonates remain the standard of care, particularly in pediatric populations, due to their ability to increase bone density and reduce fracture frequency.
In addition to traditional therapies, emerging approaches such as anabolic agents, gene-based therapies, and novel bone-targeting treatments are gaining traction as research progresses, offering new hope for improved patient outcomes.
Emerging Therapies Transforming the Osteogenesis Imperfecta Market
EVENITY (romosozumab) - Amgen/UCB Romosozumab is a humanized monoclonal antibody that targets and inhibits sclerostin, a protein that regulates bone metabolism. By promoting bone formation and reducing bone resorption, EVENITY enhances bone density and strength. It is currently approved for osteoporosis treatment and is being evaluated in Phase III clinical trials for Osteogenesis Imperfecta in pediatric patients.
Setrusumab (UX143) - Ultragenyx Pharmaceuticals/Mereo BioPharma Setrusumab is an investigational monoclonal antibody designed to inhibit sclerostin and stimulate bone formation. By improving collagen production and bone mineral density, it aims to strengthen bones and reduce fracture risk. This therapy is also in Phase III development for pediatric OI patients.
Learn more about emerging Osteogenesis Imperfecta therapies and key companies in the Osteogenesis Imperfecta market: https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market [https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Companies in the Osteogenesis Imperfecta Market
Major players actively involved in developing therapies for Osteogenesis Imperfecta include Amgen, UCB, Ultragenyx Pharmaceuticals, Angitia, Sanofi, Mereo BioPharma, and others. These companies are investing heavily in R&D to introduce innovative therapies and improve treatment outcomes.
Scope of the Osteogenesis Imperfecta Market Report
* Coverage: United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan
* Study Period: 2020-2034
* Key Companies: Amgen, UCB, Ultragenyx Pharmaceuticals, Angitia, Sanofi, Mereo BioPharma, and others
* Key Therapies: UX143 (setrusumab), EVENITY (romosozumab), PROLIA (denosumab), among others
* Comprehensive analysis of current and emerging therapies
* Evaluation of market drivers, barriers, and competitive landscape
* Insights into unmet needs, KOL perspectives, and reimbursement scenarios
Understand country-wise treatment approaches and market trends, download the full report: https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market [https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Key Insights
2. Osteogenesis Imperfecta Market Report Introduction
3. Executive Summary
4. Osteogenesis Imperfecta Market Overview at A Glance
5. Key Osteogenesis Imperfecta Events
6. Osteogenesis Imperfecta Epidemiology and Market Methodology
7. Osteogenesis Imperfecta Background and Overview
8. Osteogenesis Imperfecta Treatment and Management
9. Osteogenesis Imperfecta Epidemiology and Patient Population
10. Osteogenesis Imperfecta Patient Journey
11. Osteogenesis Imperfecta Marketed Drugs
12. Osteogenesis Imperfecta Discontinued Product
13. Osteogenesis Imperfecta Emerging Drugs
14. Osteogenesis Imperfecta: Seven Major Market Analysis
15. Osteogenesis Imperfecta Unmet Needs
16. Osteogenesis Imperfecta SWOT Analysis
17. Osteogenesis Imperfecta KOL Views
18. Osteogenesis Imperfecta Market Access and Reimbursement
19. Appendix
20. Delveinsight Capabilities
21. Disclaimer
22. About Delveinsight
About DelveInsight
DelveInsight is a leading healthcare consulting and market research firm specializing in life sciences. The company provides high-quality, data-driven insights and customized research solutions to support strategic decision-making for global clients. With a team of experienced analysts and deep industry expertise, DelveInsight delivers actionable intelligence to help organizations stay ahead in a rapidly evolving healthcare landscape.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteogenesis-imperfecta-market-to-expand-significantly-by-2034-with-advancements-in-novel-therapies-and-rising-disease-awareness-reports-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteogenesis Imperfecta Market to Expand Significantly by 2034 with Advancements in Novel Therapies and Rising Disease Awareness, Reports DelveInsight here
News-ID: 4477392 • Views: …
More Releases from ABNewswire
Hyperuricemia Clinical Trial Analysis 2026: 15+ Companies Advancing 20+ Therapie …
As per DelveInsight's assessment, globally, Hyperuricemia pipeline constitutes 15+ key companies continuously working towards developing 20+ Hyperuricemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hyperuricemia Pipeline Insight, 2026 [https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hyperuricemia Market.
The Hyperuricemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products…
Hypoglycemia Clinical Trials Surge as 15+ Companies Advance 20+ Therapies across …
As per DelveInsight's assessment, globally, Hypoglycemia pipeline constitutes 15+ key companies continuously working towards developing 20+ Hypoglycemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hypoglycemia Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoglycemia Market.
The Hypoglycemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from…
HSV-1 Keratitis Pipeline Poised for Transformational Shift by 2026, Driven by Ge …
HSV-1 Keratitis Key companies working in the market are AiCuris Anti-infective Cures AG, Shanghai BDgene Co., Ltd, Excision BioTherapeutics, Inc, and others.
"Hsv-1-Keratitis Pipeline Insight, 2026" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hsv-1-Keratitis pipeline landscape.
The report delivers a comprehensive evaluation of the evolving pipeline ecosystem, offering detailed insights into more than three leading companies and a robust portfolio of emerging therapeutic candidates targeting this vision-threatening…
Chronic Kidney Disease Market to Surpass USD 5 Billion by 2036 Across 7MM, Drive …
Key Chronic Kidney Disease Companies are ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others.
Chronic Kidney Disease market across the 7 major markets was valued at around USD 5 billion in 2025 and is projected to grow further by 2036. The United States holds the largest share at approximately…
More Releases for Osteogenesis
Distraction Osteogenesis Devices Market Is Going to Boom |• Stryker Corporatio …
Worldwide Market Reports has recently released a comprehensive research study titled "Distraction Osteogenesis Devices Market Size and Forecast 2026-2033: Breakdown by Manufacturers, Key Regions, Types, and Applications." The report has been developed using a combination of primary and secondary research methodologies, ensuring a detailed and accurate analysis. Drawing insights from both historical data and future projections, the study highlights the expected growth of the Distraction Osteogenesis Devices market in terms…
Osteogenesis Imperfecta Market: Expanding Revenue Landscape to 2034 - DelveInsig …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Distraction Osteogenesis Devices Market Growth Outlook: Current Scenario, Future …
"
The Distraction Osteogenesis (DO) Devices Market is a rapidly evolving sector within the broader orthopedic and craniofacial medical device industry. Driven by continuous technological advancements and a growing demand for effective and minimally invasive bone reconstruction techniques, the market is poised for significant expansion. DO devices provide a revolutionary approach to addressing various bone-related deformities, trauma, and congenital conditions, allowing for gradual bone lengthening and regeneration. The increasing prevalence of…
Distraction Osteogenesis Devices Market Size, Share, Development by 2024
Market Research Report Store offers a latest published report on Distraction Osteogenesis Devices Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Distraction Osteogenesis Devices market will register a 4.8% CAGR in terms of revenue, the global market size will reach US$ 214.6 million by 2024, from US$ 177.8 million in…
Distraction Osteogenesis Devices Market: Competitive Dynamics & Global Outlook 2 …
Market Research Report Store offers a latest published report on Distraction Osteogenesis Devices Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
This report focuses on the key global Distraction Osteogenesis Devices players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Distraction Osteogenesis Devices with respect…
Osteogenesis Imperfecta - Pipeline Review, H2 2018 - ResearchByMarkets.com
Osteogenesis Imperfecta - Pipeline Review, H2 2018
Summary
"Osteogenesis Imperfecta - Pipeline Review, H2 2018", provides an overview of the Osteogenesis Imperfecta (Genetic Disorders) pipeline landscape.
Osteogenesis imperfecta (OI) is a group of genetic disorders that mainly affect the bones. Mutations in the COL1A1, COL1A2, CRTAP, and P3H1 genes cause OI. An imbalance between the action of osteoclasts and osteoblasts was found in OI. Symptoms include short stature, brittle teeth, hearing loss,…
